These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18382427)

  • 1. A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling.
    Julka PK; Chacko RT; Nag S; Parshad R; Nair A; Oh DS; Hu Z; Koppiker CB; Nair S; Dawar R; Dhindsa N; Miller ID; Ma D; Lin B; Awasthy B; Perou CM
    Br J Cancer; 2008 Apr; 98(8):1327-35. PubMed ID: 18382427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 2 study of sequential neoadjuvant chemotherapy with gemcitabine and doxorubicin followed by gemcitabine and cisplatin in patients with large or locally advanced operable breast cancer: results from long-term follow-up.
    Julka PK; Chacko RT; Nag S; Parshad R; Nair A; Koppiker CB; Xue FC; Barraclough H; Dhindsa N; Seth A; Majumdar A; Puri T
    Breast Cancer; 2013 Oct; 20(4):357-62. PubMed ID: 22354450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
    Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
    Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC.
    Halim A; Wahba H
    Med Oncol; 2012 Jun; 29(2):454-8. PubMed ID: 21350875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine plus doxorubicin as first-line treatment in advanced or metastatic breast cancer (MBC), a phase II study.
    El Serafi MM; El Khodary AI; El Zawahry HR; Mansour OM; Gaballa HE
    J Egypt Natl Canc Inst; 2006 Sep; 18(3):209-15. PubMed ID: 17671530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
    Iwasaki K; Obara W; Kato Y; Takata R; Tanji S; Fujioka T
    Jpn J Clin Oncol; 2013 Feb; 43(2):193-9. PubMed ID: 23275643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial.
    Yang TS; Wang CH; Hsieh RK; Chen JS; Fung MC
    Ann Oncol; 2002 Nov; 13(11):1771-8. PubMed ID: 12419750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).
    McCarthy N; Boyle F; Zdenkowski N; Bull J; Leong E; Simpson A; Kannourakis G; Francis PA; Chirgwin J; Abdi E; Gebski V; Veillard AS; Zannino D; Wilcken N; Reaby L; Lindsay DF; Badger HD; Forbes JF;
    Breast; 2014 Apr; 23(2):142-51. PubMed ID: 24393617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of neoadjuvant gemcitabine plus doxorubicin in stage IIIB breast cancer: a preliminary report.
    Gomez H; Kahatt C; Falcon S; Santillana S; de Mendoza FH; Valdivia S; Vallejos C; Otero J; Pen DL
    Semin Oncol; 2001 Jun; 28(3 Suppl 10):57-61. PubMed ID: 11510035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results.
    Siefker-Radtke AO; Dinney CP; Shen Y; Williams DL; Kamat AM; Grossman HB; Millikan RE
    Cancer; 2013 Feb; 119(3):540-7. PubMed ID: 22914978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
    Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer.
    Artioli G; Mocellin S; Borgato L; Cappetta A; Bozza F; Zavagno G; Zovato S; Marchet A; Pastorelli D
    Anticancer Res; 2010 Sep; 30(9):3817-21. PubMed ID: 20944176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical comparison of GC regimen (gemcitabine and cisplatin) versus FEC regimen (fluorouracil, epirubicin, and cyclophosphamide) as neoadjuvant chemotherapy for breast cancer].
    Liu K; Wang GB; Cheng B; Qiu DB
    Ai Zheng; 2007 Apr; 26(4):427-30. PubMed ID: 17430667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract.
    Dodd PM; McCaffrey JA; Hilton S; Mazumdar M; Herr H; Kelly WK; Icasiano E; Boyle MG; Bajorin DF
    J Clin Oncol; 2000 Feb; 18(4):840-6. PubMed ID: 10673526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
    Sánchez-Rovira P; Jaén A; González E; Porras I; Dueñas MR; Medina B; Mohedano N; Fernández M; Martos M; Lozano A
    Clin Breast Cancer; 2000 Oct; 1(3):226-32. PubMed ID: 11899647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
    Bear HD; Tang G; Rastogi P; Geyer CE; Liu Q; Robidoux A; Baez-Diaz L; Brufsky AM; Mehta RS; Fehrenbacher L; Young JA; Senecal FM; Gaur R; Margolese RG; Adams PT; Gross HM; Costantino JP; Paik S; Swain SM; Mamounas EP; Wolmark N
    Lancet Oncol; 2015 Sep; 16(9):1037-1048. PubMed ID: 26272770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial.
    Gleeson M; Peckitt C; To YM; Edwards L; Oates J; Wotherspoon A; Attygalle AD; Zerizer I; Sharma B; Chua S; Begum R; Chau I; Johnson P; Ardeshna KM; Hawkes EA; Macheta MP; Collins GP; Radford J; Forbes A; Hart A; Montoto S; McKay P; Benstead K; Morley N; Kalakonda N; Hasan Y; Turner D; Cunningham D
    Lancet Haematol; 2018 May; 5(5):e190-e200. PubMed ID: 29703335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.
    Medioni J; Huchon C; Le Frere-Belda MA; Hofmann H; Bats AS; Eme D; Andrieu JM; Oudard S; Lecuru F; Levy E
    Drugs R D; 2011; 11(2):147-57. PubMed ID: 21679005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients.
    Nagourney RA; Link JS; Blitzer JB; Forsthoff C; Evans SS
    J Clin Oncol; 2000 Jun; 18(11):2245-9. PubMed ID: 10829044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.